448PD - Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT) von Chen, A., Kummar, S., Khan, S.S., Moore, N., Rubinstein, L., Coyne, G O’Sullivan, Zhao, Y., Palmisano, A., Williams, P., Datta, V., Sims, D., Karlovich, C., Lih, C.-J., Raghav, K.P.S., Meric-Bernstam, F., Leong, S., Waqar, S., Takebe, N., Sharon, E., Doroshow, J.

Volltext

603P - A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC) von Bendell, J., Lieu, C., Raghav, K.P.S., Argilés, G., Cubillo, A., Qu, X., Yan, Y., Merchant, M., Zeuner, H., Gallo, J.D., Segal, N.H.

Volltext

Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT) von Chen, A., Kummar, S., Khan, S.S., Moore, N., Rubinstein, L., Coyne, G O’Sullivan, Zhao, Y., Palmisano, A., Williams, P., Datta, V., Sims, D., Karlovich, C., Lih, C.-J., Raghav, K.P.S., Meric-Bernstam, F., Leong, S., Waqar, S., Takebe, N., Sharon, E., Doroshow, J.

Volltext

A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC) von Bendell, J., Lieu, C., Raghav, K.P.S., Argilés, G., Cubillo, A., Qu, X., Yan, Y., Merchant, M., Zeuner, H., Gallo, J.D., Segal, N.H.

Volltext

Supplementary Material for: Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases von B., De, R., Upadhyay, K., Liao, T., Kumala, C., Shi, G., Dodoo, J., AbiJaoude, K.L., Corrigan, G.S., Manzar, K.E., Marqueen, V., Bernard, S.S., Lee, K.P.S., Raghav, J.-N., Vauthey, C.-W., Tzeng, H.S., TranCao, G., Lee, J., Wo, T.S., Hong, C.H., Crane, B.D., Minsky, G.L., Smith, E.B., Holliday, C.M., Taniguchi, A.C., Koong, P., Das, M., Javle, E.B., Ludmir, E., Koay

Volltext bestellen

603PA phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC) von Bendell, J, Lieu, C, Raghav, K P S, Argilés, G, Cubillo, A, Qu, X, Yan, Y, Merchant, M, Zeuner, H, Gallo, J D, Segal, N H

Volltext

448PDGenomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT) von Chen, A, Kummar, S, Khan, S S, Moore, N, Rubinstein, L, Coyne, G O’Sullivan, Zhao, Y, Palmisano, A, Williams, P, Datta, V, Sims, D, Karlovich, C, Lih, C -J, Raghav, K P S, Meric-Bernstam, F, Leong, S, Waqar, S, Takebe, N, Sharon, E, Doroshow, J

Volltext

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies von Tarpgaard, Line Schmidt, Winther, Stine Brændegaard, Pfeiffer, Per

Volltext

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? von Venturini, Jacopo, Massaro, Giulia, Lavacchi, Daniele, Rossini, Daniele, Pillozzi, Serena, Caliman, Enrico, Pellegrini, Elisa, Antonuzzo, Lorenzo

Volltext

New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer von Damato, Angela, Rotolo, Martina, Caputo, Francesco, Borghi, Eleonora, Iachetta, Francesco, Pinto, Carmine

Volltext

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies von Mo, Christiana, Sterpi, Michelle, Jeon, Hyein, Bteich, Fernand

Volltext

Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives von Moati, Emilie, Overman, Michael J, Zaanan, Aziz

Volltext

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer von Yoshikawa, Ayumu, Nakamura, Yoshiaki

Volltext

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges von Wen, Xiaofen, Coradduzza, Donatella, Shen, Jiaxin, Scanu, Antonio Mario, Muroni, Maria Rosaria, Massidda, Matteo, Rallo, Vincenzo, Carru, Ciriaco, Angius, Andrea, De Miglio, Maria Rosaria

Volltext

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results von Nakano, Kenji

Volltext

Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist von Svec, Jiri, Onhajzer, Jakub, Korinek, Vladimir

Volltext

Molecular Targets for the Treatment of Metastatic Colorectal Cancer von Cohen, Romain, Pudlarz, Thomas, Delattre, Jean-François, Colle, Raphaël, André, Thierry

Volltext

Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand? von Underwood, Patrick W, Pawlik, Timothy M

Volltext

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene von Torres-Jiménez, Javier, Esteban-Villarrubia, Jorge, Ferreiro-Monteagudo, Reyes

Volltext

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma von Tanaka, Ryota, Terai, Mizue, Londin, Eric, Sato, Takami

Volltext